

Markus Kosel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/971604/publications.pdf>

Version: 2024-02-01

46
papers

2,584
citations

331670

21
h-index

254184

43
g-index

49
all docs

49
docs citations

49
times ranked

3344
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression. <i>Neuropsychopharmacology</i> , 2008, 33, 368-377.	5.4	893
2	Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients. <i>Psychiatry Research</i> , 2004, 126, 123-133.	3.3	158
3	Current status of brain imaging in anxiety disorders. <i>Current Opinion in Psychiatry</i> , 2009, 22, 96-110.	6.3	136
4	Magnetic Seizure Therapy Improves Mood in Refractory Major Depression. <i>Neuropsychopharmacology</i> , 2003, 28, 2045-2048.	5.4	111
5	Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 229-234.	1.4	102
6	Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression. <i>Journal of Psychiatric Research</i> , 2007, 41, 801-803.	3.1	97
7	Decreased frontal white-matter volume in chronic substance abuse. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 147.	2.1	94
8	Stereoselective Biotransformation of the Selective Serotonin Reuptake Inhibitor Citalopram and Its Demethylated Metabolites by Monoamine Oxidases in Human Liver. <i>Biochemical Pharmacology</i> , 1998, 56, 15-23.	4.4	83
9	Paroxetine Increases Steady-State Concentrations of (R)-Methadone in CYP2D6 Extensive but Not Poor Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 211-215.	1.4	81
10	Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex. <i>Psychiatry Research - Neuroimaging</i> , 2011, 191, 153-159.	1.8	76
11	Cytochrome P-450 activities in human and rat brain microsomes. <i>Brain Research</i> , 2000, 855, 235-243.	2.2	72
12	Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Affective Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 201-205.	5.4	58
13	Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine After Multiple Doses of Fluoxetine in Cytochrome P4502D6 Poor and Extensive Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 330-334.	1.4	57
14	Predicting Mood Changes in Bipolar Disorder Through Heartbeat Nonlinear Dynamics. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1034-1043.	6.3	51
15	Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. <i>Pharmacogenomics</i> , 2011, 12, 365-377.	1.3	49
16	Beyond the Treatment of Epilepsy: New Applications of Vagus Nerve Stimulation in Psychiatry. <i>CNS Spectrums</i> , 2003, 8, 515-521.	1.2	36
17	Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder. <i>Anesthesiology</i> , 2019, 130, 923-935.	2.5	36
18	Salivary cortisol profiles in patients remitted from recurrent depression: One-year follow-up of a mindfulness-based cognitive therapy trial. <i>Journal of Psychiatric Research</i> , 2012, 46, 80-86.	3.1	34

#	ARTICLE	IF	CITATIONS
19	Cognitive Functioning in Patients Remitted from Recurrent Depression: Comparison with Acutely Depressed Patients and Controls and Follow-up of a Mindfulness-Based Cognitive Therapy Trial. <i>Cognitive Therapy and Research</i> , 2013, 37, 1004-1014.	1.9	32
20	Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 590-597.	1.4	32
21	Phenomenology of racing and crowded thoughts in mood disorders: A theoretical reappraisal. <i>Journal of Affective Disorders</i> , 2010, 121, 189-198.	4.1	29
22	Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 85-95.	4.8	23
23	Telemonitoring with respect to Mood Disorders and Information and Communication Technologies: Overview and Presentation of the PSYCHE Project. <i>BioMed Research International</i> , 2014, 2014, 1-12.	1.9	22
24	Mechanisms and State of the Art of Vagus Nerve Stimulation. <i>Journal of ECT</i> , 2002, 18, 189-192.	0.6	21
25	Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. <i>International Journal of Neuropsychopharmacology</i> , 2000, 3, 55-60.	2.1	19
26	Cerebral blood flow effects of acute intravenous heroin administration. <i>European Neuropsychopharmacology</i> , 2008, 18, 278-285.	0.7	19
27	Brain stimulation therapies for neuropsychiatric disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 681-695.	1.8	17
28	Novel NEXMIF pathogenic variant in a boy with severe autistic features, intellectual disability, and epilepsy, and his mildly affected mother. <i>Journal of Human Genetics</i> , 2018, 63, 847-850.	2.3	15
29	Diminished GABAA Receptor-Binding Capacity and a DNA Base Substitution in a Patient with Treatment-Resistant Depression and Anxiety. <i>Neuropsychopharmacology</i> , 2004, 29, 347-350.	5.4	14
30	Development of inhibitory synaptic inputs on layer 2/3 pyramidal neurons in the rat medial prefrontal cortex. <i>Brain Structure and Function</i> , 2018, 223, 1999-2012.	2.3	14
31	In vitro metabolism of citalopram by monoamine oxidase B in human blood. <i>European Neuropsychopharmacology</i> , 2001, 11, 75-78.	0.7	13
32	Novel physical treatments for major depression: vagus nerve stimulation, transcranial magnetic stimulation and magnetic seizure therapy. <i>Current Opinion in Psychiatry</i> , 2004, 17, 15-20.	6.3	13
33	Pattern of regional cerebral blood-flow changes induced by acute heroin administration – a perfusion MRI study. <i>Journal of Neuroradiology</i> , 2007, 34, 322-329.	1.1	13
34	Interaction of psychotropic drugs with monoamine oxidase in rat brain. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 1125-1130.	2.4	12
35	Pegylated human interferon alpha 2a does not induce depression-associated changes in mice. <i>Psychiatry Research</i> , 2011, 185, 243-247.	3.3	9
36	Pharmacokinetic Consequences of a Citalopram Treatment Discontinuation. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 263.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Pain interventions in adults with intellectual disability: A scoping review and pharmacological considerations. <i>European Journal of Pain</i> , 2020, 24, 875-885.	2.8	8
38	Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 607-610.	1.4	8
39	Prevalence of Polypharmacy and Inappropriate Medication in Adults With Intellectual Disabilities in a Hospital Setting in Switzerland. <i>Frontiers in Psychiatry</i> , 2021, 12, 614825.	2.6	6
40	The utility of the autism-spectrum quotient to screen for autism spectrum disorder in adults with attention deficit/hyperactivity disorder. <i>Psychiatry Research</i> , 2022, 312, 114580.	3.3	3
41	Brain Stimulation in Depression. , 2005, , 403-425.		2
42	Repetitive transcranial magnetic stimulation (rTMS) in depression. <i>Poiesis & Praxis</i> , 2006, 4, 111-127.	0.3	2
43	Cross-cultural preliminary validation of a measure of social vulnerability in people with intellectual disabilities. <i>Journal of Intellectual and Developmental Disability</i> , 2021, 46, 67-79.	1.6	2
44	Adaptation Process and Psychometric Properties of the French Version of the Health of the Nation Outcome Scales for People with Learning Disabilities. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 0, , 1-12.	2.0	1
45	Neurodevelopmental Disorders: From Pathophysiology to Novel Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 623.	3.2	1
46	TOP-ID: a Delphi technique-guided development of a prescription and deprescription tool for adults with intellectual disabilities. <i>BMJ Open</i> , 2020, 10, e039208.	1.9	0